Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAP4K4 | O95819 | 2/20 | 0.49 |
| ▸ | MAPT | P10636 | 1/20 | 0.48 |
| ▸ | HRH3 | Q9Y5N1 | 4/20 | 0.46 |
| ▸ | GRM3 | Q14832 | 3/20 | 0.46 |
| ▸ | PKM | P14618 | 1/20 | 0.43 |
| ▸ | PDE10A | Q9Y233 | 1/20 | 0.42 |
| ▸ | FPR1 | P21462 | 1/20 | 0.42 |
| ▸ | FPR2 | P25090 | 1/20 | 0.42 |
| ▸ | PTGER4 | P35408 | 2/20 | 0.41 |
| ▸ | KHK | P50053 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30790756 | 0.84 | HRH3 (0.55) | HRH3PDE10A | |
| SCHEMBL15034199 | 0.83 | PDE10A (0.56) | MAP4K4PDE10AFPR1FPR2PTGER4 | |
| SCHEMBL21135741 | 0.80 | PDE10A (0.56) | MAP4K4PDE10AFPR1FPR2PTGER4 | |
| SCHEMBL21135455 | 0.80 | MAPT (0.53) | MAPTGRM3PKM | |
| SCHEMBL19355691 | 0.80 | MAP4K4 (0.49) | MAP4K4PDE10AFPR1FPR2PTGER4 | |
| SCHEMBL16046361 | 0.79 | MAP4K4 (0.48) | MAP4K4MAPTHRH3GRM3PKM | |
| Hydrochloric Acid SCHEMBL16046701 | 0.78 | MAP4K4 (0.47) | MAP4K4MAPTHRH3GRM3PKM | |
| SCHEMBL14650779 | 0.77 | UBE2T (0.51) | MAPTHRH3 | |
| SCHEMBL21135514 | 0.77 | MAP4K4 (0.52) | MAP4K4FPR1FPR2KHK | |
| SCHEMBL21135724 | 0.77 | MAPT (0.60) | MAPTGRM3PKMPDE10A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3371196-B1 | HETEROCYCLIC COMPOUNDS AS INHIBITORS OF PLATELET AGGREGATION | UNIV MONTREAL (CA) | 2021-10-27 | — | — | EP | disclosed |
| US-10329307-B2 | Heterocyclic compounds as inhibitors of platelet aggregation | UNIVERSITE DE MONTREAL (CA) | 2019-06-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10329307-B2 | Heterocyclic compounds as inhibitors of platelet aggregation | F12, F2, F3 | MAP4K4 1927/4885MAPT 1241/4885HRH3 87/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.